Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2019-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for ABL Bio Inc. for the first quarter of 2019 (January 1, 2019, to March 31, 2019). It contains detailed company information, management discussion, capital changes, and financial data, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is used to disclose share transactions or changes in ownership status by company insiders (directors/executives). According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2019-05-14 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by ABL Bio. It details the patent name, content, and strategic application. Since it is a regulatory announcement regarding a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it falls under the general regulatory filing category.
2019-05-13 Korean
기타경영사항(특허권취득)(자율공시)(DLL4와 VEGF에 특이적으로 결합하는 신규 이중표적 단백질 및 이의 용도)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by ABL Bio. It details the patent name, its technical application, and its strategic importance to the company's clinical pipeline. Since this is a specific corporate announcement regarding a business development event that does not fit into financial reporting, dividend, or governance categories, it falls under the general regulatory filing category.
2019-04-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an entity's shareholding in a listed company crosses a specific threshold or changes significantly. This falls under the 'Major Shareholding Notification' category.
2019-04-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) to report changes in shareholdings by major shareholders or insiders. Based on the provided definitions, this falls under 'Major Shareholding Notification' (MRQ) as it details a change in ownership percentage (a decrease of 3.94%) by a major shareholder (Korea Investment Global Pharma-Ecosystem Private Equity Fund).
2019-04-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.